The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-κB target genes by interaction with NFKBIZ

Oncogene

Volumn 28, Issue 2, 2009, Pages 270-278

  Goransson M ^a   Andersson, M K ^a   Forni, C ^b   Stahlberg A ^a   Andersson, C ^a   Olofsson, A ^a   Mantovani, R ^b   Aman P ^a,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

DDIT3; FUS; MLS RCLS; NF B; NFKBIZ; Sarcoma

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; NUCLEAR FACTOR; ONCOPROTEIN; PROTEIN FUS DDIT3; PROTEIN NFKBIZ; UNCLASSIFIED DRUG;

ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; GENE CONTROL; GENE INTERACTION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOLECULAR CLONING; MYXOSARCOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; UPREGULATION;

ACUTE-PHASE PROTEINS; BINDING SITES; CCAAT-ENHANCER-BINDING PROTEINS; CELL LINE, TUMOR; CELL NUCLEUS; FIBROSARCOMA; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; LIPOCALINS; LIPOSARCOMA, MYXOID; NEOPLASM PROTEINS; NF-KAPPA B; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTO-ONCOGENE PROTEINS; RNA-BINDING PROTEIN FUS; TRANSCRIPTION FACTOR CHOP; TRANSCRIPTION, GENETIC;

EID: 58249116717     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.378     Document Type: Article

References (50)

1. Åman P, Panagopoulos I, Lassen C, Fioretos T, Mencinger M, Toresson H et al. (1996). Expression patterns of the human sarcoma-associated genes FUS and EWS and the genomic structure of FUS. Genomics 37: 1-8.
2. Åman P, Ron D, Mandahl N, Fioretos T, Heim S, Arheden K et al. (1992). Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). Genes Chromosomes Cancer 5: 278-285.
3. Basile A, Sica A, d'Aniello E, Breviario F, Garrido G, Castellano M et al. (1997). Characterization of the promoter for the human long pentraxin PTX3. Role of NF-kappaB in tumor necrosis factor-alpha and interleukin-1beta regulation. J Biol Chem 272: 8172-8178.
4. Biegel JA, Conard K, Brooks JJ. (1993). Translocation (11;22)(p13;q12): primary change in intra-abdominal desmoplastic small round cell tumor. Genes Chromosomes Cancer 7: 119-121.
5. Bratt T. (2000). Lipocalins and cancer. Biochim Biophys Acta 1482: 318-326.
6. Brinckerhoff CE, Rutter JL, Benbow U. (2000). Interstitial collagenases as markers of tumor progression. Clin Cancer Res 6: 4823-4830.
7. Caretti G, Salsi V, Vecchi C, Imbriano C, Mantovani R. (2003). Dynamic recruitment of NF-Y and histone acetyltransferases on cell-cycle promoters. J Biol Chem 278: 30435-30440.
8. Chen Z, Ruffner DE. (1998). Amplification of closed circular DNA in vitro. Nucleic Acids Res 26: 1126-1127.
9. Crozat A, Åman P, Mandahl N, Ron D. (1993). Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 363: 640-644.
10. Diffin F, Porter H, Mott MG, Berry PJ, Brown KW. (1994). Rapid and specific diagnosis of t(11;22) translocation in paediatric Ewing's sarcoma and primitive neuroectodermal tumours using RNA-PCR. J Clin Pathol 47: 562-564.
11. Engström K, Willen H, Kåbjörn-Gustafsson C, Andersson C, Olsson M, Göransson M et al. (2006). The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells. Am J Pathol 168: 1642-1653.
12. Göransson M, Elias E, Ståhlberg A, Olofsson A, Andersson C, Åman P. (2005). Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression. Int J Cancer 115: 556-560.
13. Göransson M, Wedin M, Åman P. (2002). Temperature-dependent localization of TLS-CHOP to splicing factor compartments. Exp Cell Res 278: 125-132.
14. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. (1999). NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 19: 2690-2698.
15. Kitamura H, Kanehira K, Okita K, Morimatsu M, Saito M. (2000). MAIL, a novel nuclear I kappa B protein that potentiates LPS-induced IL-6 production. FEBS Lett 485: 53-56.
16. Kovar H. (2005). Context matters: the hen or egg problem in Ewing's sarcoma. Semin Cancer Biol 15: 189-196.
17. Kovar H, Zoubek A, Pfleiderer C, Jug G, Auinger A, Aryee D et al. (1994). The EWS gene rearrangement in Ewing tumors: key to the disease. Klin Padiatr 206: 196-200.
18. Law WJ, Cann KL, Hicks GG. (2006). TLS, EWS and TAF15: a model for transcriptional integration of gene expression. Brief Funct Genomic Proteomic 5: 8-14.
19. Libermann TA, Baltimore D. (1990). Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 10: 2327-2334.
20. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. (1995). A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 23: 1686-1690.
21. Matsuo S, Yamazaki S, Takeshige K, Muta T. (2007). Crucial roles of binding sites for NF-kappaB and C/EBPs in IkappaB-zeta-mediated transcriptional activation. Biochem J 405: 605-615.
22. Matsusaka T, Fujikawa K, Nishio Y, Mukaida N, Matsushima K, Kishimoto T et al. (1993). Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci USA 90: 10193-10197.
23. Morohoshi F, Ootsuka Y, Arai K, Ichikawa H, Mitani S, Munakata N et al. (1998). Genomic structure of the human RBP56/hTAFII68 and FUS/TLS genes. Gene 221: 191-198.
24. Motoyama M, Yamazaki S, Eto-Kimura A, Takeshige K, Muta T. (2005). Positive and negative regulation of nuclear factor-kappaB-mediated transcription by IkappaB-zeta, an inducible nuclear protein. J Biol Chem 280: 7444-7451.
25. Mukaida N, Mahe Y, Matsushima K. (1990). Cooperative interaction of nuclear factor-kappa B- and cis-regulatory enhancer binding protein-like factor binding elements in activating the interleukin-8 gene by pro-inflammatory cytokines. J Biol Chem 265: 21128-21133.
26. Nakopoulou L, Giannopoulou I, Gakiopoulou H, Liapis H, Tzonou A, Davaris PS. (1999). Matrix metalloproteinase-1 and -3 in breast cancer: correlation with progesterone receptors and other clinicopathologic features. Hum Pathol 30: 436-442.
27. Ohno T, Rao VN, Reddy ES. (1993). EWS/Fli-1 chimeric protein is a transcriptional activator. Cancer Res 53: 5859-5863.
28. Oikawa K, Ishida T, Imamura T, Yoshida K, Takanashi M, Hattori H et al. (2006). Generation of the novel monoclonal antibody against TLS/EWS-CHOP chimeric oncoproteins that is applicable to one of the most sensitive assays for myxoid and round cell liposarcomas. Am J Surg Pathol 30: 351-356.
29. Olofsson A, Willen H, Göransson M, Engström K, Meis-Kindblom JM, Stenman G et al. (2004). Abnormal expression of cell cycle regulators in FUS-CHOP carrying liposarcomas. Int J Oncol 25: 1349-1355.
30. Panagopoulos I, Höglund M, Mertens F, Mandahl N, Mitelman F, Åman P. (1996). Fusion of the EWS and CHOP genes in myxoid liposarcoma. Oncogene 12: 489-494.
31. Panagopoulos I, Mandahl N, Ron D, Höglund M, Nilbert M, Mertens F et al. (1994). Characterization of the CHOP breakpoints and fusion transcripts in myxoid liposarcomas with the 12;16 translocation. Cancer Res 54: 6500-6503.
32. Perez-Losada J, Pintado B, Gutierrez-Adan A, Flores T, Banares-Gonzalez B, del Campo JC et al. (2000a). The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice. Oncogene 19: 2413-2422.
33. Perez-Losada J, Sanchez-Martin M, Rodriguez-Garcia MA, Perez-Mancera PA, Pintado B, Flores T et al. (2000b). Liposarcoma initiated by FUS/TLS-CHOP: the FUS/TLS domain plays a critical role in the pathogenesis of liposarcoma. Oncogene 19: 6015-6022.
34. Rabbitts TH, Forster A, Larson R, Nathan P. (1993). Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet 4: 175-180.
35. Riggi N, Cironi L, Provero P, Suva ML, Stehle JC, Baumer K et al. (2006). Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res 66: 7016-7023.
36. Ron D, Habener JF. (1992). CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev 6: 439-453.
37. Sanchez Garcia I, Rabbitts TH. (1994). Transcriptional activation by TAL1 and FUS-CHOP proteins expressed in acute malignancies as a result of chromosomal abnormalities. Proc Natl Acad Sci USA 91: 7869-7873.
38. Schwarzbach MH, Koesters R, Germann A, Mechtersheimer G, Geisbill J, Winkler S et al. (2004). Comparable transforming capacities and differential gene expression patterns of variant FUS/CHOP fusion transcripts derived from soft tissue liposarcomas. Oncogene 23: 6798-6805.
39. Ståhlberg A, Håkansson J, Xian X, Semb H, Kubista M. (2004). Properties of the reverse transcription reaction in mRNA quantification. Clin Chem 50: 509-515.
40. Sun SC, Xiao G. (2003). Deregulation of NF-kappaB and its upstream kinases in cancer. Cancer Metastasis Rev 22: 405-422.
41. Thelin-Järnum S, Göransson M, Burguete AS, Olofsson A, Åman P. (2002). The myxoid liposarcoma specific TLS-CHOP fusion protein localizes to nuclear structures distinct from PML nuclear bodies. Int J Cancer 97: 446-450.
42. Thelin-Järnum S, Lassen C, Panagopoulos I, Mandahl N, Åman P. (1999). Identification of genes differentially expressed in TLS-CHOP carrying myxoid liposarcomas. Int J Cancer 83: 30-33.
43. Totzke G, Essmann F, Pohlmann S, Lindenblatt C, Janicke RU, Schulze-Osthoff K. (2006). A novel member of the IkappaB family, human IkappaB-zeta, inhibits transactivation of p65 and its DNA binding. J Biol Chem 281: 12645-12654.
44. Trinh DV, Zhu N, Farhang G, Kim BJ, Huxford T. (2008). The nuclear I kappaB protein I kappaB zeta specifically binds NF-kappaB p50 homodimers and forms a ternary complex on kappaB DNA. J Mol Biol 379: 122-135.
45. Uranishi H, Tetsuka T, Yamashita M, Asamitsu K, Shimizu M, Itoh M et al. (2001). Involvement of the pro-oncoprotein TLS (translocated in liposarcoma) in nuclear factor-kappa B p65-mediated transcription as a coactivator. J Biol Chem 276: 13395-13401.
46. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A et al. (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
47. Vincenti MP, Coon CI, Brinckerhoff CE. (1998). Nuclear factor kappaB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1beta-stimulated synovial fibroblasts. Arthritis Rheum 41: 1987-1994.
48. Yamazaki S, Muta T, Takeshige K. (2001). A novel IkappaB protein, IkappaB-zeta, induced by proinflammatory stimuli, negatively regulates nuclear factor-kappaB in the nuclei. J Biol Chem 276: 27657-27662.
49. Zinszner H, Albalat R, Ron D. (1994). A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. Genes Dev 8: 2513-2526.
50. Zinszner H, Immanuel D, Yin Y, Liang FX, Ron D. (1997). A topogenic role for the oncogenic N-terminus of TLS: nucleolar localization when transcription is inhibited. Oncogene 14: 451-461.